Ebastine in allergic rhinitis and chronic idiopathic urticaria

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 63, Issue SUPPL. 89, 2008, Pages 1-20

  Sastre, J ^a,b  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Allergic rhinitis; Antihistamines; Chronic urticaria; Ebastine; H 1 receptor antagonists

Indexed keywords

ASTEMIZOLE; CAREBASTINE; CETIRIZINE; CHLORPHENIRAMINE; CIMETIDINE; CLEMASTINE; DESLORATADINE; DIAZEPAM; DIPHENHYDRAMINE; EBASTINE; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; ERYTHROMYCIN STEARATE; FEXOFENADINE; IMMUNOGLOBULIN E; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; PLACEBO; PSEUDOEPHEDRINE; RUPATADINE; TERFENADINE; TRIPROLIDINE;

ABDOMINAL PAIN; ADVERSE OUTCOME; ALERTNESS; ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ANTICHOLINERGIC EFFECT; ASTHMA; ATOPIC DERMATITIS; BIOEQUIVALENCE; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; CLINICAL TRIAL; COGNITIVE DEFECT; COLD URTICARIA; COMBINATION CHEMOTHERAPY; COMMON COLD; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; COST OF ILLNESS; CYTOKINE PRODUCTION; DERMOGRAPHIC URTICARIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DROWSINESS; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPEPSIA; EOSINOPHIL; EPISTAXIS; FOOD; FOOD DRUG INTERACTION; HEADACHE; HEART ARRHYTHMIA; HISTAMINE RELEASE; HUMAN; IDIOPATHIC DISEASE; IMMUNOPATHOGENESIS; INSECT BITE; INSOMNIA; MONOTHERAPY; NAUSEA; NOSE POLYP; PERENNIAL RHINITIS; POLLEN ALLERGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RHINITIS; RHINOMANOMETRY; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; TORSADE DES POINTES; URTICARIA; VISUOMOTOR COORDINATION; XEROSTOMIA;

ANIMALS; BUTYROPHENONES; CHRONIC DISEASE; HISTAMINE H1 ANTAGONISTS; HUMANS; PIPERIDINES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

EID: 55949097044     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01897.x     Document Type: Review

References (98)

1. Bousquet J, Van Cauwenberge P, Khaltaev N Allergic rhinitis and its impact on asthma (ARIA): In collaboration with the World Health Organization; executive summary. Allergy 2002 57 : 841 855.
2. Schoenwetter WF, Dupclay L, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004 20 : 305 317.
3. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007 28 : 3 9.
4. Bousquet J, Van Cauwenberge P, Bachert C, Canonica GW, Demoly P, Durham R et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 2003 58 : 192 197.
5. 2LEN/EDF guideline: management of urticaria. Allergy 2006 61 : 321 331.
6. Hurst M, Spencer M. Ebastine: an update of its use in allergic disorders. Drugs 2000 59 : 981 1006.
7. Van Cauwenberge P, De Belder T, Sys L. A review of the second-generation antihistamine ebastine for the treatment of allergic disorders. Expert Opin Pharmacother 2004 5 : 1807 1813.
8. Bousquet J, Van Cauwenberge P, Khaltaev N : ARIA workshop Group Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl. 5 S147 S334.
9. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001 108 (Suppl. B S2 S8.
10. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic asthma in Europe. Eur Respir J 2004 24 : 758 764.
11. Howarth PH, Holmberg K. Allergic rhinitis an increasing clinical problem. Allergy 1995 50 : 4 5.
12. Koh YY, Chang KK. The development of asthma in patients with allergic rhinitis. Curr Opin Allergy Clin Immunol 2003 3 : 159 164.
13. Bousquet J, Demarteau N, Mullol J et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005 60 : 788 794.
14. Dessi P, Allaert FA, Urbinelli R, Verriere JL. Medico-economic aspects of the management of perennial allergic rhinitis in general medicine. Allerg Immunol (Paris) 1998 30 : 277 283.
15. 2LEN guideline definition, classification and diagnosis of urticaria. Allergy 2006 61 : 316 320.
16. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007 87 : 196 205.
17. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997 136 : 197 201.
18. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003 3 : 363 368.
19. Rossenwasser L. New insights into the pathophysiology of allergc rhinitis. Allergy Asthma Proc 2007 28 : 10 15.
20. Canonica GW. Introduction to nasal and pulmonary allergy cascade. Allergy 2002 57 : 8 12.
21. Van Cauwenberge P, Bachert C, Passalacqua G, Bosquet J, Canonica GW, Durham SR et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000 55 : 116 134.
22. Vincent J, Liminana R, Meredith PA, Reid JL. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 1988 26 : 497 502.
23. Rohatagi S, Gillen M, Aubeneau M, Jan C, Pandit B, Jensen BK et al. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. Int J Clin Pharmacol Ther 2001 39 : 126 134.
24. Yamaguchi T, Hashizume T, Matsuda M, Sakashita M, Fujii T, Sekine Y et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung 1994 44 : 59 64.
25. Hampel F, Gillen M, Rohatagi SS, Lim J, Georges G. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis. J Clin Pharmacol 2002 42 : 1097 1104.
26. Huang M-Y, Argenti D, Wilson J, Garcia J, Heald D. Pharmacokinetics and electrocardiographic effect of ebastine in young vs elderly healthy subjects. Am J Ther 1998 5 : 153 158.
27. Huang M-Y, Wilson J, Argenti D, Heald D, Ziemniak J. Comparative pharmacokinetics of ebastine/carebastine in liver cirrhosis and healthy volunteers following administration of a 10 mg ebastine tablet. Pharm Res 1993 10 (Suppl. 10 S390.
28. Hashizume T, Mise M, Terauchi Y, Luan O, Fujii T, Miyazaki H et al. N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 1998 26 : 566 571.
29. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 2002 300 : 298 304.
30. Liu KH, Kim MG, Lee DJ, Yoon YJ, Kim MJ, Shon JH et al. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 2006 34 : 1793 1797.
31. Laboratorios Almirall SA. Spanish Summary of product characteristics: Ebastine 2004.
32. Lasseter KC, Dilzer SC, Vargas R, Waldman S, Noveck RJ. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clin Pharmacokinet 2004 43 : 121 129.
33. Simons FER, Watson WTA, Simons KJ. Pharmacokinetics and pharmacodynamics of ebastine in children. J Pediatr 1993 122 : 641 646.
34. Noveck RJ, Preston RA, Swan SK. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment. Clin Pharmacokinet 2007 46 : 525 534.
35. Chaikin P, Gillen MS, Malik M, Pentikis H, Rhodes GR, Roberts DJ. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol 2005 59 : 346 354.
36. van Rooij J, Schoemaker HC, Bruno R, Reinhoudt JF, Breimer DD, Cohen AF. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine. Br J Pharmacol 1993 35 : 661 663.
37. Mattila MJ, Aranko K, Kuitunen T. Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine. Br J Clin Pharmacol 1993 35 : 272 277.
38. Mattila MJ, Kuitunen T, Pletan Y. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. Eur J Clin Pharmacol 1992 43 : 179 184.
39. Frossard N, Benabdesselam O, Purohit A, Mounedji N, Pauli G. Activity of ebastine (10 and 20 mg) and cetirizine at 24 h of a steady state treatment in the skin of healthy volunteers. Fundam Clin Pharmacol 2000 14 : 409 413.
40. Gispert J, Antonijoan R, Barbanoj M, Dich I, Garcia E, Esbri R et al. Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges. Ann Allergy Asthma Immunol 2002 89 : 259 264.
41. Barbanoj MJ, Antonijoan RM, Garcia-Gea C, Morte A, Gich I, Gispert J et al. A study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine-induced skin reactivity. Int Arch Allergy Immunol 2003 132 : 263 267.
42. Nelson HS, Bucher B, Buchmeier A, Oppenheimer J, Garcia J. Suppression of the skin reaction to histamine by ebastine. Ann Allergy Asthma Immunol 1995 74 : 442 447.
43. van Steekelenburg J, Clement PAR, Beel MHL. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 2002 57 : 346 350.
44. Frossard N, Vital-Durand D, Mounedji N, Valleteau A. Duration of the antihistaminic effect after discontinuation of ebastine. Allergy 2001 56 : 553 557.
45. Frossard N, Melac M, Benabdesselam O, Pauli G. Consistency of the efficacy of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol 1998 80 : 61 65.
46. Wood-Baker R, Holgate ST. Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma. Agents Action 1990 30 : 284 286.
47. Campbell A, Michel F-B, Bremard-Oury C, Crampette L, Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs 1996 52 (Suppl. 1 15 19.
48. Horiguchi T, Tachikawa S, Kasahara J, Shiga M, Kondo R, Miyazaki J et al. Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma. Clin Drug Invest 1999 17 : 435 440.
49. Ciprandi G, Cirillo I, Mora F, La Rosa M. Ebastine improves nasal symptoms and airflow and affects response to decongestion test in patients with persistent allergic rhinitis: a pilot study. Allergy Asthma Proc 2007 28 : 578 581.
50. Ankier SI, Warrington SJ. A double-blind placebo-controlled study of the efficacy and tolerability of ebastine against hayfever in general practice. J Int Med 1989 226 : 453 458.
51. de Molina M, Cadahia A, Cano L, Sanz A. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis. Drug Invest 1989 1 : 40 46.
52. Peláez A. Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis. Drug 1996 52 (Suppl. 1 35 38.
53. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996 52 (Suppl. 1 20 25.
54. Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996 76 : 507 512.
55. Hampel F, Howland W, van Bavel J, Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 2004 14 : 56 63.
56. Ratner P, Hampel F, van Bavel J, Howland W. Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. Int Arch Allergy Immunol 2004 133 : 371 379.
57. Ratner PH, Lim JC, Georges GC, Ebastine Study Group. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol 2000 105 (6 Pt 1 1101 1107.
58. Grossman J. A multicentre double-blind placebo controlled dose response study of ebastine in ragweed SA patients. Allergy 1996 51 (Suppl. 41.
59. Bernstein D, Del Rio M, Georges GC, Valleteau A. Placebo-controlled trial of ebastine 20 mg and 10 mg once daily vs loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis (SAR). Eur J Allergy Clin Immunol 1999 54 (Suppl. 52 150.
60. Luria X, Robert M, Antepara I et al. A double-blind placebo controlled study of the efficacy and tolerability of ebastine and loratadine in seasonal allergic rhinitis patients [abstract]. Allergy 1995 50 (Suppl. 199.
61. Ratner P, Falqués M, Chuecos F, Esbrí R, Gispert J, Peris F et al. Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Int Arch Allergy Immunol 2005 138 : 312 318.
62. Ratner P, Hampel F, Gispert J. Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis. Methods Find Exp Clin Pharmacol 2003 25 : 111 115.
63. Bousquet J, Gaudano EM, Palma Carlos AG, Staudinger H. A 12-week, placebo-controlled study of the efficay and safety of ebastine 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Allergy 1999 54 : 562 568.
64. Picado Vallés C, Cadahia García A, Bahima C, Cantudo C, Sanz Amaro A, Zayas Sanza M. Ebastine in perennial allergic rhinitis. Ann Allergy 1991 67 : 615 618.
65. Davies RJ, European Multicentre Study Group. Efficacy and tolerability comparison of ebastine 10 and 20 mg with loratadine 10 mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clin Drug Invest 1998 16 : 413 420.
66. Murris-Espin M, Melac M, Charpentier J-C, Didier A. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998 80 : 399 403.
67. Benavente V, Eseverri J-L, Botey J, Marin A. Ebastine, traitement de la rhinite persistante chez l'enfant. Allerg Immunol 1996 28 : 277 281.
68. Peyri J, Vidal J, Marrón J, Fonseca E, Suárez E, Ledo A et al. Ebastine in chronic urticaria: a double-blind placebo-controlled study. J Dermatol Treat 1991 2 : 51 53.
69. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 1996 52 (Suppl. 1 30 34.
70. Magerl M, Schmolke J, Siebenhaar F, Zuberbier T, Metz M, Maurer M. Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy 2007 62 : 1465 1468.
71. Magerl M, Schmolke J, Siebenhaar F, Zuberbier T, Metz M, Maurer M. Dermographic urticaria symptoms can be safely prevented by ebastine (abstract plus poster). XX World Allergy Congress 2007, Dec 2-6, Bangkok.
72. Luria X, Robert M, Garci'a A Clinical test of ebastina plus pseudoefedrina in seasonal allergic rhinitis [abstract 75]. XIX Congresson Nacionale la Sociedad Espanôla de Alergologia e Immunologia Clinica Oct 12-15, Tenerife, 1994.
73. Karpinnen A, Petman L, Jukunen A, Kautiainen H, Vaalasti A, Reunala T. Treatment of mosquito bites with ebastine: a field trial. Acta Derm Venereol 2000 80 : 114 116.
74. Robert M, Llorens M, Garcia E, Luria X, Common Cold Collaborative Group. Efficacy and tolerability of ebastine 10 mg plus pseudoephedrine 120 mg in the symptomatic relief of the common cold. Eur J Int Med 2004 15 : 242 247.
75. Moss AJ, Chaikin P, Garcia JD, Gillen M, Roberts DJ, Morganroth J. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy 1999 29 (Suppl. 3 200 205.
76. Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001 52 : 201 204.
77. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001 12 : 411 420.
78. Gispert J, Esbri R, Garcia E et al. Ebastine has no effect on QTc interval at doses up to 50 times the therapeutic dose [abstract 779]. Allergy 2002 57 (Suppl. 73 243 244.
79. Hindmarch I, Shamzi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999 29 (Suppl. 3 133 142.
80. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y et al. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol 2001 52 : 501 509.
81. Vincent J, Sumner DJ, Reid JL. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br J Clin Pharmacol 1988 26 : 503 508.
82. Hopes H, Meuret G-H, Ungethüm W, Leopold G, Wiemann H. Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG. Eur J Clin Pharmacol 1992 42 : 55 59.
83. Brookhuis KA, de Vries G, de Waard D. Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance. Br J Clin Pharacol 1993 36 : 67 70.
84. Hindmarch I, Shamsi Z. The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers. Curr Med Res Opin 2001 17 : 273 281.
85. O'Hanlon JF, Ramackers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 1995 50 : 234 242.
86. Salvà M, Carreño B, Pintos M, Jansat JM, Rosales MJ, Megard Y. Phase I, single dose, open-label, randomized, crossover bio-equivalence studies of ebastine 10 mg and 20 mg regular tablets vs. 10 and 20 mg fast-dissolving tablets in healthy male volunteers. J Invest Allergol Clin Immunol 2004 14 (Suppl. 1 S5.
87. Antonijoan RM, García-Gea C, Puntes M et al. A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults. Clin Drug Invest 2007 27 : 453 461.
88. Antonijoan RM, García-Gea C, Puntes M et al. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) vs desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults. Clin Ther 2007 29 : 814 822.
89. Roger A, Fortea J, Mora S, Artés M. Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets versus regular tablets in allergic rhinitis. Expert Rev Pharmacoeconomics Outcomes Res 2008 8 : 337 342.
90. Roger A, Plazas Fernández MJ, Galván Cervera J, Heras Navarro J, Artés Ferragud M, Gabarrón Hortal E. Preferred attributes of the new fast dissolving tablet (FDT) formulation of ebastine in patients with allergy. J Outcome Res 2006 10 : 13 22.
91. Roger A, Plazas Fernández MJ, Galván Cervera J, Heras Navarro J, Artés Ferragud M, Gabarron Hortal E. Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectancies. Allergol et Immunopathol 2006 34 : 107 112.
92. Roger A, Plazas Fernández MJ, Galván Cervera J, Heras Navarro J, Artés Ferragud M, Montilla Garzón L. Aceptación, expectativas y satisfación de la formulación flas para el tratamiento de la alergia. Farmcologia 2007 372 : 2 10.
93. Roger A, Fortea J, Plazas MJ, Asensio D, Mora S, Gonzáles-Rojas N. Evaluation of the patient's satisfaction with the new ebastine formulation in patients suffering from allergic rhinitis [abstract 619]. Allergy 2007 62 : 225. Plus Poster Presented at XXVI Congress EAACI, 2007 Jun 9-13, Göteberg.
94. Roger A, Fortea J, Mora S, Artés M. Ebastine fast-dissolving tablets vs regular tablets: acceptability and preference in patients with allergic rhinitis. Rev Clin Pharmacol 2008 1 : 381 389.
95. 2LEN). Allergy 2006 61 : 1086 1096.
96. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen). Allergy 2008 63 (Suppl. 86 8 160.
97. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000 55 : 7 16.
98. Horak F. Clinical advantages of dual activity in allergic rhinitis. Allergy 2000 55 (Suppl. 64 34 39.